Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of adjuvant chemotherapy added to ovarian suppression plus endocrine therapy in premenopausal endocrine-responsive breast cancer
2005-002626-59Phase 3Terminated
- Sponsor
- International Breast Cancer Study Group
- Start
- Jul 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, exemestane and triptorelin in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoint: Disease-free survival. Started Jul 2005; status: terminated.
02
Drugs
tamoxifenexemestanetriptorelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-002626-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002626-59.